{"OMIM ID": "OMIM:617771", "DISEASE": "Epileptic Encephalopathy, Early Infantile, 57", "RECORD": "Rare disease patients have complex clinical representations. Patients with Epileptic Encephalopathy, Early Infantile, 57 present clinical features that include seizures, developmental delay, movement disorders, cognitive impairment, and sleep disorders. These patients have a high risk of developing psychiatric disorders, including depression, anxiety, and autism spectrum disorders.\n\nThe purpose of this study was to evaluate the efficacy and safety of cannabidiol (CBD) in patients with treatment-. Some special cases also present with sleep disorders, such as Kleine-Levin syndrome, a rare disorder characterized by recurrent episodes of hypersomnia, hyperphagia, cognitive impairment, and behavioral changes.\n\nThe study included patients with a diagnosis of Kleine-Levin syndrome, who were treated with CBD for a period of six weeks. The results showed that the treatment was well tolerated and that it was associated with a significant improvement in the quality of life of patients.\n\nThe authors concluded that CBD is a safe and effective treatment option for patients with Kleine-Levin syndrome.\n\nThe study was published in the journal Seizure.. The main symptomatic differences of Epileptic Encephalopathy, Early Infantile, 57 from similar diseases is that the seizures are the first symptom to appear.\n\nThe study was conducted by researchers from the University of S\u00e3o Paulo, Brazil. The study included patients with Epileptic Encephalopathy, Early Infantile, 57 who were treated with CBD for a period of six weeks.\n\nThe results showed that", "SUMMARY": " the treatment was well tolerated and that it was associated with a significant improvement in the quality of life of patients.\n\nThe authors concluded that CBD is a safe and effective treatment option for patients with Epileptic Encephalopathy, Early Infant"}